Lauren M. Mitteer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lauren M. Mitteer has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Diva D. De Leon
Congenital Hyperinsulinism Center, Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia , Philadelphia, PA 19104
6 shared publications Kara E. Boodhansingh
3 shared publicationsKatherine Lord
3 shared publications- Winifred Sigal
Division of Endocrinology and Diabetes, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
3 shared publications - Charles A. Stanley
Division of Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
2 shared publications - Christine Juliana
Congenital Hyperinsulinism Center, Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia , Philadelphia, PA 19104
2 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-17
Clinical Presentation and Outcomes of Insulinomas in Pediatric Patients
Introduction. Insulinomas are the leading cause of hyperinsulinemic hypoglycemia in adults, but they can also present during childhood, and, when they do, diagnosis and localization of the lesion can be difficult. Moreover, differentiating between congenital hyperinsulinism (HI) and pediatric insulinomas is challenging because both diseases have similar presentation. Our objective was to review the clinical presentation, diagnostic characteristics, and success of methods for localization, treatment, and outcomes in pediatric patients with insulinomas. Methods. Retrospective study of patients with confirmed insulinoma treated at a single academic pediatric hospital between 2006 and 2024. Descriptive statistics and logistic regression models were used to quantify the data and discriminate between groups, respectively. The optimal operating point (OOP) for diagnostic laboratory data was used to maximize discrimination between insulinomas and congenital hyperinsulinism (HI), with prediction accuracy determined by the sensitivity and specificity at the OOP. Results. We reviewed the records of 23 patients with insulinoma with a median age at presentation of 13 years. A positive family history of multiple endocrine neoplasia type 1 (MEN1) was recorded in 22%. The most common presenting symptom was altered mental status. Median plasma insulin and beta-hydroxybutyrate (BOHB) concentrations during hypoglycemia were 8.8 uIU/mL (61.1 pmol/L) and 0.3 mmol/L, respectively. Most patients had four imaging studies completed to localize their insulinoma. Twenty of the 23 patients reviewed had a single lesion successfully resected and were cured. Of these 20 patients, 12 had 18F-Fluoro-dihydroxyphenylalanine (18F-DOPA) positron emission tomography/computed tomography (PET/CT) completed, of which nine were positive (75%). Three patients had initial lesions localized and successfully resected but continued to have hypoglycemia requiring medical management. Median duration from presentation to surgery was 9 weeks. When comparing the critical samples of patients with insulinomas and HI, the combination of BOHB and insulin-like growth factor binding protein 1 (IGFBP-1) at the time of hypoglycemia yielded a sensitivity and specificity of 0.89 and 0.84, respectively, for insulinoma versus HI when using a multivariate function on our cohorts. Conclusion. In this series, successful treatment of insulinomas took, on average, 9 weeks from diagnosis. Multiple imaging modalities were employed for preoperative lesion localization, with 18F-DOPA PET/CT and MRI being the most successful. Improved imaging modalities are needed to localize insulinomas in pediatric patients and reduce the time between diagnosis and resection. We propose an algorithm to differentiate between pediatric insulinomas and congenital hyperinsulinism using laboratory data to quicken diagnosis and lessen time to treatment.
- 18 May 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-17
Open AccessClinical Presentation and Outcomes of Insulinomas in Pediatric Patients
Introduction. Insulinomas are the leading cause of hyperinsulinemic hypoglycemia in adults, but they can also present during childhood, and, when they do, diagnosis and localization of the lesion can be difficult. Moreover, differentiating between congenital hyperinsulinism (HI) and pediatric insulinomas is challenging because both diseases have similar presentation. Our objective was to review the clinical presentation, diagnostic characteristics, and success of methods for localization, treatment, and outcomes in pediatric patients with insulinomas. Methods. Retrospective study of patients with confirmed insulinoma treated at a single academic pediatric hospital between 2006 and 2024. Descriptive statistics and logistic regression models were used to quantify the data and discriminate between groups, respectively. The optimal operating point (OOP) for diagnostic laboratory data was used to maximize discrimination between insulinomas and congenital hyperinsulinism (HI), with prediction accuracy determined by the sensitivity and specificity at the OOP. Results. We reviewed the records of 23 patients with insulinoma with a median age at presentation of 13 years. A positive family history of multiple endocrine neoplasia type 1 (MEN1) was recorded in 22%. The most common presenting symptom was altered mental status. Median plasma insulin and beta-hydroxybutyrate (BOHB) concentrations during hypoglycemia were 8.8 uIU/mL (61.1 pmol/L) and 0.3 mmol/L, respectively. Most patients had four imaging studies completed to localize their insulinoma. Twenty of the 23 patients reviewed had a single lesion successfully resected and were cured. Of these 20 patients, 12 had 18F-Fluoro-dihydroxyphenylalanine (18F-DOPA) positron emission tomography/computed tomography (PET/CT) completed, of which nine were positive (75%). Three patients had initial lesions localized and successfully resected but continued to have hypoglycemia requiring medical management. Median duration from presentation to surgery was 9 weeks. When comparing the critical samples of patients with insulinomas and HI, the combination of BOHB and insulin-like growth factor binding protein 1 (IGFBP-1) at the time of hypoglycemia yielded a sensitivity and specificity of 0.89 and 0.84, respectively, for insulinoma versus HI when using a multivariate function on our cohorts. Conclusion. In this series, successful treatment of insulinomas took, on average, 9 weeks from diagnosis. Multiple imaging modalities were employed for preoperative lesion localization, with 18F-DOPA PET/CT and MRI being the most successful. Improved imaging modalities are needed to localize insulinomas in pediatric patients and reduce the time between diagnosis and resection. We propose an algorithm to differentiate between pediatric insulinomas and congenital hyperinsulinism using laboratory data to quicken diagnosis and lessen time to treatment.
- Open Access
- 14 April 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-11
Natural History of the Hyperinsulinism/Hyperammonemia Syndrome: A Retrospective Review Incorporating Patient-Centered Data
Introduction: The hyperinsulinism/hyperammonemia (HI/HA) syndrome manifests with fasting and protein-induced hypoglycemia, hyperammonemia, and neurodevelopmental features including epilepsy. There is a paucity of information describing the natural history of the HI/HA syndrome. Methods: A retrospective review of patients with HI/HA syndrome evaluated at the Congenital Hyperinsulinism Centers at the Children’s Hospital of Philadelphia or Cook Children’s Medical Center or who contributed to the Congenital Hyperinsulinism International HI Global Registry (HIGR) was conducted to describe the natural history of the HI/HA syndrome with particular focus on treatment and neurodevelopmental outcomes. Results: A total of 66 patients (36 female) from the medical record review and 15 patients (7 female, 3 sex not reported) from HIGR were included. Median age at last follow-up was 13.1 years (IQR, 6.8–19.0 years) in the medical record cohort and median age at survey completion was 11.6 years (IQR, 5.5–18.0 years) among HIGR participants. Eighty percent of the medical record cohort and 82% of HIGR participants were treated with diazoxide and most continued treatment over the follow-up period. Epilepsy (29% of medical record cohort, 33% HIGR participants) and neurodevelopmental issues (64% medical record cohort, 73% HIGR participants) were common. Conclusion: Our findings underscore the importance of longitudinal endocrine and neuropsychological follow-up for patients with HI/HA syndrome and demonstrate the potential value of patient-driven registry data to address persistent knowledge gaps in the natural history of rare diseases.
- 14 April 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-11
Open AccessNatural History of the Hyperinsulinism/Hyperammonemia Syndrome: A Retrospective Review Incorporating Patient-Centered Data
Introduction: The hyperinsulinism/hyperammonemia (HI/HA) syndrome manifests with fasting and protein-induced hypoglycemia, hyperammonemia, and neurodevelopmental features including epilepsy. There is a paucity of information describing the natural history of the HI/HA syndrome. Methods: A retrospective review of patients with HI/HA syndrome evaluated at the Congenital Hyperinsulinism Centers at the Children’s Hospital of Philadelphia or Cook Children’s Medical Center or who contributed to the Congenital Hyperinsulinism International HI Global Registry (HIGR) was conducted to describe the natural history of the HI/HA syndrome with particular focus on treatment and neurodevelopmental outcomes. Results: A total of 66 patients (36 female) from the medical record review and 15 patients (7 female, 3 sex not reported) from HIGR were included. Median age at last follow-up was 13.1 years (IQR, 6.8–19.0 years) in the medical record cohort and median age at survey completion was 11.6 years (IQR, 5.5–18.0 years) among HIGR participants. Eighty percent of the medical record cohort and 82% of HIGR participants were treated with diazoxide and most continued treatment over the follow-up period. Epilepsy (29% of medical record cohort, 33% HIGR participants) and neurodevelopmental issues (64% medical record cohort, 73% HIGR participants) were common. Conclusion: Our findings underscore the importance of longitudinal endocrine and neuropsychological follow-up for patients with HI/HA syndrome and demonstrate the potential value of patient-driven registry data to address persistent knowledge gaps in the natural history of rare diseases.
- Open Access
- 10 March 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , 2242-2250
Noncoding Variants in Intron 2 of HK1 Associated With Hyperinsulinism With Variable Clinical Phenotype
Introduction Non-coding variants in HK1 were first associated with congenital hyperinsulinism (HI) in a large family with diazoxide-responsive HI in 2008. Since then, additional cases have been reported in the literature with non-coding variants in HK1 associated with variable HI phenotypes. Methods We sequenced a 350bp region in intron 2 of HK1 in 281 individuals with genetics negative HI to identify additional cases related to non-coding HK1 variants and to characterize the clinical features of these cases. Results We identified 16 unique non-coding variants in intron 2 of HK1 in 18 individuals with genetics negative HI (18/281, 6.4%). In seven cases (7/18, 39%), the HK1 variant was inherited from a parent (2 maternal, 5 paternal), two are known to be affected with HI. In nine cases, the HK1 variant was de novo (9/18, 50%). The age of presentation of HI ranged from day of life one to 21 months of age. Seven cases had diazoxide-responsive HI (7/18, 39%). Eleven cases were diazoxide unresponsive (11/18, 61%); five underwent pancreatectomy at ages ranging from six months to three years of age. Conclusions Non-coding variants in intron 2 of the HK1 gene have now been associated with HI in a growing number of cases. Our findings suggest that a significant proportion of individuals with negative genetics in genes currently known to be associated with HI may harbor HK1 intron 2 variants. Identifying these cases is important for clinical care as well as for assessing recurrence risk for families.
- 10 March 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , 2242-2250
Open AccessNoncoding Variants in Intron 2 of HK1 Associated With Hyperinsulinism With Variable Clinical Phenotype
Introduction Non-coding variants in HK1 were first associated with congenital hyperinsulinism (HI) in a large family with diazoxide-responsive HI in 2008. Since then, additional cases have been reported in the literature with non-coding variants in HK1 associated with variable HI phenotypes. Methods We sequenced a 350bp region in intron 2 of HK1 in 281 individuals with genetics negative HI to identify additional cases related to non-coding HK1 variants and to characterize the clinical features of these cases. Results We identified 16 unique non-coding variants in intron 2 of HK1 in 18 individuals with genetics negative HI (18/281, 6.4%). In seven cases (7/18, 39%), the HK1 variant was inherited from a parent (2 maternal, 5 paternal), two are known to be affected with HI. In nine cases, the HK1 variant was de novo (9/18, 50%). The age of presentation of HI ranged from day of life one to 21 months of age. Seven cases had diazoxide-responsive HI (7/18, 39%). Eleven cases were diazoxide unresponsive (11/18, 61%); five underwent pancreatectomy at ages ranging from six months to three years of age. Conclusions Non-coding variants in intron 2 of the HK1 gene have now been associated with HI in a growing number of cases. Our findings suggest that a significant proportion of individuals with negative genetics in genes currently known to be associated with HI may harbor HK1 intron 2 variants. Identifying these cases is important for clinical care as well as for assessing recurrence risk for families.
- Open Access
- 8 March 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-10
Double Trouble: When Focal and Diffuse Hyperinsulinism Occur Simultaneously
Introduction: Congenital hyperinsulinism (HI) may be diazoxide-responsive or diazoxide-unresponsive. Patients with diazoxide-unresponsive HI are further classified based on having the diffuse or focal form of the disease, with different management strategies associated with each form. While patients with HI typically have only one form of the disease, here we report 3 patients who had both focal and diffuse HI. Case Presentation: Three patients with diazoxide-unresponsive HI were transferred to our hospital for further management. All 3 patients had genetic testing which was equivocal or initially negative. Given their diazoxide status and not wanting to miss a focal lesion that was amenable to a surgical cure, all 3 patients underwent imaging with 18 F-L 3,4-dihydroxyphenylalanine positron emission tomography which identified focal pancreatic lesions in all 3 patients. They all had surgical resection of the lesions. Biopsies of the pancreas outside of the lesions noted rare or scattered islet cell nucleomegaly, indicative of diffuse disease, and subsequent fasting studies to determine if patients were cured revealed ongoing HI. Further review of genetic results suggested a mechanism for both focal and diffuse HI occurring in each of the patients. For all 3 patients, their ongoing HI could be managed with diazoxide following removal of the focal lesion. Conclusion: Focal and diffuse HI can occur in the same patient. Following resection of focal pancreatic lesions, the patients require careful evaluations for evidence of ongoing HI, and depending on the genetic results, diazoxide may be a management option for ongoing HI in a subset of these patients.
- 8 March 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-10
Open AccessDouble Trouble: When Focal and Diffuse Hyperinsulinism Occur Simultaneously
Introduction: Congenital hyperinsulinism (HI) may be diazoxide-responsive or diazoxide-unresponsive. Patients with diazoxide-unresponsive HI are further classified based on having the diffuse or focal form of the disease, with different management strategies associated with each form. While patients with HI typically have only one form of the disease, here we report 3 patients who had both focal and diffuse HI. Case Presentation: Three patients with diazoxide-unresponsive HI were transferred to our hospital for further management. All 3 patients had genetic testing which was equivocal or initially negative. Given their diazoxide status and not wanting to miss a focal lesion that was amenable to a surgical cure, all 3 patients underwent imaging with 18 F-L 3,4-dihydroxyphenylalanine positron emission tomography which identified focal pancreatic lesions in all 3 patients. They all had surgical resection of the lesions. Biopsies of the pancreas outside of the lesions noted rare or scattered islet cell nucleomegaly, indicative of diffuse disease, and subsequent fasting studies to determine if patients were cured revealed ongoing HI. Further review of genetic results suggested a mechanism for both focal and diffuse HI occurring in each of the patients. For all 3 patients, their ongoing HI could be managed with diazoxide following removal of the focal lesion. Conclusion: Focal and diffuse HI can occur in the same patient. Following resection of focal pancreatic lesions, the patients require careful evaluations for evidence of ongoing HI, and depending on the genetic results, diazoxide may be a management option for ongoing HI in a subset of these patients.
- Open Access
- 15 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , 1874-1885
Functional evaluation of pancreatic islets from patients with Beckwith–Wiedemann syndrome and congenital hyperinsulinism
Context: Beckwith–Wiedemann Syndrome (BWS) is an overgrowth syndrome caused by various genetic or epigenetic abnormalities in a cluster of imprinted genes on chromosome 11p15. Congenital hyperinsulinism (HI) is one of the cardinal features of BWS, but the pathophysiology of HI in BWS has not been clearly defined. Objective: We describe the islet phenotype of a series of infants with severe HI and comorbid BWS who required pancreatectomy for intractable hypoglycemia. Methods: The cases are a subset of HI patients who required pancreatectomy and had Beckwith–Wiedemann Syndrome. Molecular testing for BWS was performed by SNP array and chromosome 11p15 methylation analysis. Functional analysis of insulin secretion in pancreatic islets isolated from pancreatectomy samples was completed with perifusion experiments and cytosolic Ca2+ measurements. Results: Similar to what we had previously described in islets isolated from the pancreas of infants with HI due to inactivating mutations in the KATP channel, BWS–HI islets have elevated concentrations of cytosolic calcium and secrete insulin in response to stimulation with a physiologic mixture of amino acids. However, unlike KATPHI islets, most BWS–HI islets retain responsiveness to stimulation with glucose and the KATP channel inhibitor glyburide. Through RNAseq analysis, we observed that expression of KCNQ1, encoding the pore-forming subunit of a voltage-gated K + channel (Kv7.1), is reduced in BWS–HI islets compared to normal human islets (3-fold; P = 4.5 × 10-7). Conclusion: Our expression analysis and functional evaluation of islets isolated from BWS–HI patients reveal the spectrum of insulin secretion responses found across BWS etiologies and suggest a potential role for loss of KCNQ1 expression in the complex pathophysiology responsible for the hyperinsulinism in BWS.
- 15 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , 1874-1885
Open AccessFunctional evaluation of pancreatic islets from patients with Beckwith–Wiedemann syndrome and congenital hyperinsulinism
Context: Beckwith–Wiedemann Syndrome (BWS) is an overgrowth syndrome caused by various genetic or epigenetic abnormalities in a cluster of imprinted genes on chromosome 11p15. Congenital hyperinsulinism (HI) is one of the cardinal features of BWS, but the pathophysiology of HI in BWS has not been clearly defined. Objective: We describe the islet phenotype of a series of infants with severe HI and comorbid BWS who required pancreatectomy for intractable hypoglycemia. Methods: The cases are a subset of HI patients who required pancreatectomy and had Beckwith–Wiedemann Syndrome. Molecular testing for BWS was performed by SNP array and chromosome 11p15 methylation analysis. Functional analysis of insulin secretion in pancreatic islets isolated from pancreatectomy samples was completed with perifusion experiments and cytosolic Ca2+ measurements. Results: Similar to what we had previously described in islets isolated from the pancreas of infants with HI due to inactivating mutations in the KATP channel, BWS–HI islets have elevated concentrations of cytosolic calcium and secrete insulin in response to stimulation with a physiologic mixture of amino acids. However, unlike KATPHI islets, most BWS–HI islets retain responsiveness to stimulation with glucose and the KATP channel inhibitor glyburide. Through RNAseq analysis, we observed that expression of KCNQ1, encoding the pore-forming subunit of a voltage-gated K + channel (Kv7.1), is reduced in BWS–HI islets compared to normal human islets (3-fold; P = 4.5 × 10-7). Conclusion: Our expression analysis and functional evaluation of islets isolated from BWS–HI patients reveal the spectrum of insulin secretion responses found across BWS etiologies and suggest a potential role for loss of KCNQ1 expression in the complex pathophysiology responsible for the hyperinsulinism in BWS.
- Open Access
- 8 January 2025
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 99 (4) , 518-527
Congenital Hyperinsulinism and Long QT Syndrome Attributable to a Variant in KCNE1
Introduction: This is a report of a child with congenital hyperinsulinism associated with a loss-of-function variant in KCNE1. KCNE1 encodes a human potassium channel accessory (beta) subunit that modulates potassium channel Kv7.1 (encoded by KCNQ1). Loss-of-function pathogenic variants in either the KCNQ1 or KCNE1 genes result in long QT syndrome by causing prolongation in the action potential duration at the cellular level. In addition to long QT syndrome, the phenotype associated with loss-of-function pathogenic variants in KCNQ1 is characterized by postprandial hyperinsulinemic hypoglycemia. Case Presentation: Clinical data for the proband were extracted from the medical records. The proband presented with fasting hypoglycemia due to hyperinsulinism in early childhood as well as postprandial hypoglycemia triggered by carbohydrates and by protein. Whole-exome sequencing was undertaken in genomic DNA isolated from proband and both parents. Whole-exome sequencing revealed a variant in KCNE1 inherited from the father, who also has a history of hyperinsulinism. Both the patient and father were subsequently diagnosed with long QT syndrome. The proband and father underwent phenotype testing including fasting test, oral glucose tolerance test, oral protein tolerance test, and exercise tolerance test. Conclusions: This case illustrates that loss-of-function variants in KCNE1, similar to KCNQ1, are associated with a cardiac and a beta cell phenotype, and thus, this patient population should be screened for hypoglycemia, particularly in the postprandial state.
- 8 January 2025
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 99 (4) , 518-527
Open AccessCongenital Hyperinsulinism and Long QT Syndrome Attributable to a Variant in KCNE1
Introduction: This is a report of a child with congenital hyperinsulinism associated with a loss-of-function variant in KCNE1. KCNE1 encodes a human potassium channel accessory (beta) subunit that modulates potassium channel Kv7.1 (encoded by KCNQ1). Loss-of-function pathogenic variants in either the KCNQ1 or KCNE1 genes result in long QT syndrome by causing prolongation in the action potential duration at the cellular level. In addition to long QT syndrome, the phenotype associated with loss-of-function pathogenic variants in KCNQ1 is characterized by postprandial hyperinsulinemic hypoglycemia. Case Presentation: Clinical data for the proband were extracted from the medical records. The proband presented with fasting hypoglycemia due to hyperinsulinism in early childhood as well as postprandial hypoglycemia triggered by carbohydrates and by protein. Whole-exome sequencing was undertaken in genomic DNA isolated from proband and both parents. Whole-exome sequencing revealed a variant in KCNE1 inherited from the father, who also has a history of hyperinsulinism. Both the patient and father were subsequently diagnosed with long QT syndrome. The proband and father underwent phenotype testing including fasting test, oral glucose tolerance test, oral protein tolerance test, and exercise tolerance test. Conclusions: This case illustrates that loss-of-function variants in KCNE1, similar to KCNQ1, are associated with a cardiac and a beta cell phenotype, and thus, this patient population should be screened for hypoglycemia, particularly in the postprandial state.